US › Healthcare

Kala Pharmaceuticals Inc (KALA)

US · Healthcare · Biotechnology

$0.74-5.11%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-1.6M
Profit YoY
+81.9%
EPS
$-0.14

Key statistics

Market cap
$15.1M
Forward P/E
0.0
P/B
1.33
Book value
$0.58
EPS (TTM)
$-102.01
52-week high
$1,030.00
52-week low
$0.59
50-day MA
$1.86
200-day MA
$18.98
Beta
-2.28

Analyst view

Analysts rate Kala Pharmaceuticals Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $1.50.

Shareholding

Insiders
1.24%
Institutions
0.62%

Largest institutional holders

FundStake
Renaissance Technologies Corp0.04%
Citadel Advisors Llc0.03%
Geode Capital Management, LLC0.03%
Virtu Financial LLC0.02%
ADAR1 Capital Management LLC0.02%
Vanguard Group Inc0.01%
GSA Capital Partners LLP0.01%
UBS Group AG0.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kala Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.